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patients (26.0%-42.5% p< 0.0001), while reductions in mean SABA fills were also 
observed in Severe patients (20.1%; p= 0.0328). ConClusions: Omalizumab ini-
tiation was associated with significant reduction in PACE and MU in patients with 
moderate or severe persistent asthma.
PRS8
IndIRect comPaRISon of exaceRbatIon fRequency between 
aclIdInIum and tIotRoPIum In PatIentS wIth chRonIc obStRuctIve 
PulmonaRy dISeaSe
Lee H., Choi S.E., Bae E., Lim E.A., Kim J., Park H.
Korea University, Yeongi-gun, South Korea
objeCtives: The purpose of this study is to compare the frequency of exacer-
bations between aclidinium and tiotropium in patients with chronic obstructive 
pulmonary disease (COPD). Methods: Through a systematic literature search in 
Medline (PubMed), we included randomized controlled trials that evaluated the 
exacerbation frequency of aclidinium 200µg and 400µg twice a day and tiotropium 
18µg once a day regimens compared to placebo. Inclusion criteria were at least 
12 weeks of treatment from January 1990 to January 2014, an age over 40, current 
or former smokers, and diagnosis with moderate to very severe COPD. The main 
outcome is the frequency of exacerbation. Indirect comparison analysis was per-
formed to estimate the odds ratio of exacerbation between aclidinium and tiotro-
pium. Results: After screening 278 full-text articles, we identified 19 clinical trials 
that total 19,741 COPD patients were participated: 3 trials of aclidinium 200µg and 
400µg BID and 16 trials of tiotropium 18µg QD. tiotropium 18µg was associated with 
a significant reduction in exacerbation compared with placebo (OR 0.90; 95% CI 0.84 
to 0.96). Other two anticholinergic agents showed comparable effects in reducing 
exacerbation compared with placebo: aclidinium 200µg (OR 0.73; 95% CI 0.53 to 1.01) 
and aclidinium 400µg (OR 0.72; 95% CI 0.52 to 1.00). Aclidinium 200µg (OR 0.84; 95% 
CI 0.603-1.167) and aclidinium 400µg (OR 0.83; 95% CI 0.592 -1.156) BID showed the 
similar frequency of exacerbation to tiotropium 18µg QD. ConClusions: Our study 
substantiates that tiotropium 18µg provides superior effects on lowering the risk of 
exacerbation compared with placebo but there was no significant difference in the 
frequency of exacerbations between aclidinium and tiotropium.
PRS9
tReatment Plan comPaRISon: an obSeRvatIonal Study of the maRche 
RegIon
Sciattella P.1, Marcellusi A.2, Mennini F.S.3
1University of Rome “Tor Vergata” Italy, Rome, Italy, 2University of Rome, Rome, Italy, 3University 
of Rome “Tor Vergata”, Italy, Rome, Italy
objeCtives: To estimate the number of users of Theophylline (ATC: R03DA04) 
and Doxofylline (ATC: R03DA11) for the treatment of chronic asthma in adults, 
in the Marche Region. Moreover, we wanted to estimate the cost of the two treat-
ments, taking into account the prescriptions of other drugs associated with 
them. Methods: The drug prescriptions were extracted from the Information 
System of the Pharmaceutical Prescriptions of the Marche Region (PHARM), con-
taining all the recipes sent by pharmacies within the region and reimbursed by the 
National Health System. The number of prescriptions per year has been obtained 
by selecting all the recipes for each ATC code in the years 2008-2012, while the 
number of users has been estimated by identifying the subjects who received at 
least one prescription of the ATC codes of interest. The number of concomitant 
prescriptions was estimated by selecting all the recipes for potentially associated 
ATC, dispenced between 5 days before and 5 days following the prescription of ATC 
codes. The price of prescriptions has been calculated using the information “price” 
contained in the PHARM record. Results: For both drugs, the users are approxi-
mately 5,000 per year in the study period. Theophylline had a mean base price lower 
than Doxofylline (4.81€ vs 6.37€ per prescription); however, Theophylline was more 
associated than Doxofylline (34.4% vs 23.7%) with other drugs for the treatment of 
Asthma. Consequently, the total treatment cost for Theophylline was equal to 33.65€ 
vs a total cost for Doxofylline equal to 22.49€ (+ 49.6%). ConClusions: The PHARM 
allows the estimate of drugs’ utilization, taking into account the overall patient’s 
treatment plan. In our study, the prescription of the first ATC code is more associ-
ated with prescriptions of other drugs, and this implies an increasing in the cost of 
the treatment plan despite a lower average initial price.
PRS10
a databaSe Study to InveStIgate the IncIdence of anaPhylaxIS and 
the PReScRIPtIon Rate of Self-InjectIon ePInePhRIne In jaPan
Shima D.1, Ii Y.1, Yamamoto Y.2, Nagayasu S.2, Fujimoto Y.1
1Pfizer Japan Inc, Tokyo, Japan, 2MinaCare co. ltd, Tokyo, Japan
objeCtives: A database research was conducted to investigate the incidence of 
anaphylaxis/shock using a Japanese health-claims database (HDB). In addition, 
the prescription rate of self-injection epinephrine was investigated among those 
patients with anaphylaxis for the management of future reactions. Methods: 
A Japanese HDB which contains approximately 1.8 million subjects covered by 
employment-based health insurance (MinaCare Co. Ltd) was used for this retrospec-
tive study. In order to identify actual anaphylaxis/shock precisely, diagnosis recorded 
in the claims based on ICD-10 code (T78.0, T78.2 and T88.6) was combined with claim 
records of medical practice and prescriptions. Specifically, prescription for epineph-
rine/adrenaline or oxygen inhalation therapy was required for “anaphylactic shock” 
and the use of an infusion therapy or venous catheter was required for detect-
ing “anaphylaxis (except for anaphylactic shock)”. For this study, the data associ-
ated with events occurring in fiscal years 2010 to 2013 (2010/4/1 to 2013/3/31) were 
included. Results: Of approximately 2.9 million person-years of observations, 13.3 
anaphylactic shock events per 100,000 person-years (crude rate) were identified. The 
rate was 42.9 per 100,000 person-years when non-shock anaphylaxis events were 
considered. The age-specific anaphylactic shock event rates (per 100,000 person-
years) were: 27.6 (0-6 years), 12.8 (7-12 years), 11.0 (13-18 years), and 11.9 (> 18 years). 
Among the 389 anaphylactic shock events, etiologies of anaphylaxis were food 113 
objeCtives: To assess the relative efficacy of umeclidinium bromide 62.5 mcg OD 
(UMEC) versus tiotropium bromide 18 mcg OD (TIO), aclidinium bromide 400 mcg 
BID (AB) and glycopyrronium bromide 50 mcg OD (GLYCO). Methods: A systematic 
literature review was performed to identify RCTs ≥ 12 weeks duration comparing 
TIO, AB, GLYCO or UMEC to placebo in adult patients with COPD. Random effects 
meta-analyses were performed by pooling results of each treatment vs. placebo 
on change from baseline at 12 and 24 weeks in trough FEV1, SGRQ total score, TDI 
focal score and rescue medication use. The results were synthesized by using an 
indirect treatment comparison (ITC) within a frequentist framework based on the 
Bucher method. Scenario analyses were performed to evaluate the robustness of 
the results to variations in the included studies and assumptions. Results: At 12 
weeks, ITC results show that treatment with UMEC resulted in a comparable but 
numerically higher change from baseline in trough FEV1 compared to TIO [18.06mL 
(95%CI: -19.11, 55.23, p= 0.341)], AB [35.77mL (95%CI: -7.84, 79.38, p= 0.108)] and GLYCO 
[27.86mL (95%CI: -8.74, 64.45, p= 0.136)]. At 24 weeks, UMEC resulted in comparable 
trough FEV1 values vs. TIO (p= 0.854), AB (p= 0.663) and GLYCO (p= 0.777). UMEC also 
resulted in comparable TDI focal scores and rescue medication use at both time 
points compared with TIO, AB and GLYCO. UMEC resulted in numerically lower 
(better) change from baseline at 12 weeks in SGRQ total score compared with TIO 
[-2.65 (95%CI: -7.09, 1.79, p= 0.242)], AB [-2.68 (95%CI: -7.12, 1.75, p= 0.235)] and GLYCO 
[-2.15 (95%CI: -6.60, 2. 31, p= 0.345)]. At 24 weeks there was no statistically significant 
difference in change from baseline in SGRQ total score between UMEC, TIO, AB and 
GLYCO. ConClusions: UMEC showed comparable efficacy to TIO, AB and GLYCO 
on trough FEV1, SGRQ, TDI and rescue medication use at 12 and 24 weeks.
PRS6
SyStematIc RevIew of obSeRvatIonal StudIeS and RctS of 
omalIzumab In SeveRe PeRSIStent alleRgIc aSthma and meta-
analySIS feaSIbIlIty aSSeSSment
Bergrath E.1, Hwa Ong S.2, Bousquet J.3, Balwin M.4, Manga V.2, Rao S.2, Cope S.5
1Mapi, Inc., Boston, MA, USA, 2Novartis Pharma AG, Basel, Switzerland, 3University of 
Montpellier, Montpellier, France, 4Novartis Pharma AG (Employed by Novartis at time of 
systematic literature review), Basel, Switzerland, 5Mapi, Toronto, ON, Canada
objeCtives: To compare the effectiveness of omalizumab versus standard of care 
(SOC) based on randomized controlled trials (RCTs) compared with ‘real-world’, 
single cohort, observational studies that assess patients ‘before and after’ the use of 
omalizumab. Methods: A systematic literature review was conducted to identify 
RCTs and observational studies that assessed omalizumab in patients with severe 
persistent allergic asthma. Study and patient characteristics, outcome definitions, 
and differences in baseline risk and observed study effects were compared in terms 
of exacerbations and hospitalizations across the RCTs and observational stud-
ies. Results: 11 RCTs and 24 observational studies were identified. A wide range 
of clinically significant exacerbation rates was observed across RCTs in terms of 
baseline risk (SOC: 0.40–2.86) and the treatment effect (rate ratio [RR]: 0.39–0.75). This 
differed from observational studies in terms of baseline risk (before omalizumab: 
3.48–6.00) and the treatment effect (RRs: 0.12–0.46). A limited range of severe exac-
erbation rates was observed in RCTs regarding baseline risk (SOC: 0.42–0.48) and the 
treatment effect (RR: 0.50–0.56). However, considerable differences were identified 
in observational studies in terms of baseline risk (before omalizumab: 2.20–4.50) 
and the treatment effect (RR: 0.05–0.39). In terms of hospitalization rates, a limited 
range was observed for RCTs with respect to baseline risk (SOC: 0.12–0.17) and the 
treatment effect (RR: 0.12–0.54). Again, a wider range was observed across the obser-
vational studies in terms of baseline risk (before omalizumab: 0.32–4.45) and the 
treatment effect (RR: 0.09–0.71). ConClusions: ‘Real-world’ evidence reinforces 
the efficacy of omalizumab in patients with severe allergic asthma derived from 
RCTs, although differences in potential treatment effect modifiers were identified. 
Patients in observational studies may represent a more severe population compared 
with those in RCTs.
PRS7
ImPact of omalIzumab on PooR aSthma contRol eventS and 
medIcatIon utIlISatIon In PatIentS wIth modeRate oR SeveRe 
PeRSIStent aSthma
Yu T.C.1, Nazareth T.1, Turner S.J.2, Raimundo K.3, Zhou H.4, Ortiz B.1, Li L.5
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharmaceuticals, East 
Hanover, NJ, USA, 3Genentech Inc., South San Francisco, CA, USA, 4KMK Consulting Inc., Florham 
Park, NJ, USA, 5Career International Inc., Shanghai, China
objeCtives: Poor asthma control is associated with increased health care cost 
in patients with moderate or severe asthma. Here we evaluate the impact of 
omalizumab on poor asthma control events (PACE) and medication utilisation 
(MU) in a case-crossover study of US patients with moderate or severe persistent 
asthma. Methods: Truven MarketScan database was used to compare PACE 
(hospitalisation, ER visit, corticosteroid [CS] burst or ≥ 7 short-acting beta-agonist 
[SABA] fills) and MU for 1 year pre/post omalizumab exposure, during the period 
1-January-2007 to 30-September-2012. Included in the analysis were patients aged 
≥ 12 years who had 1 inpatient or 2 outpatient Asthma claims (ICD-9= 493. XX) and 
used omalizumab continuously for 1 year, with 2 years continuous coverage (1 year 
pre/post omalizumab index date). Patients were categorized as Moderate or Severe 
based on their most recent 8 weeks of continuous, NHLBI-guideline-recommended, 
therapy preceding omalizumab. Results: In total, 429 patients (mean age, 46.6 
years; female, 59.0%; Moderate= 340, Severe= 89) were included in the analysis. 
Omalizumab was associated with reductions in proportions of All, Moderate, and 
Severe asthma patients with PACE (41.3%, 48.3%, 17.2%, respectively; all p< 0.05). 
Specifically, reductions in patients with ≥ 1 asthma-related hospitalisation, ≥ 1 
asthma-related ER visit, ≥ 2 CS bursts, and ≥ 7 SABA fills in the Moderate group 
(Moderate: 55.9%, 77.8%, 53.8%, and 40.6%, respectively; all p≤ 0.0196) drove reduc-
tions in All patients (all p≤ 0.0159). Reductions in patients with ≥ 1 OCS fill and ≥ 1 
SABA fill were observed in All and Moderate patients (20.3%–26.1%; all p< 0.0001); 
reductions in mean OCS fills and mean SABA fills were observed in All and Moderate 
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couple of different scenarios of smoking initiation. Birth and death rates of the 
general population are assumed to be the average of the previous decade. Relative 
Risk of mortality is assumed to be the same. Results: Smoking prevalence in 
2024 is estimated to be 18.5%, even with alternate hypotheses around smoking 
initiation in the 2012-2022 decade. ConClusions: Aging of smoker population 
will continue to contribute to reducing prevalence of smokers. Existing dynamic 
forecasting models were re-created and used to estimate smoker prevalence using 
recent data.
RefeRenCes
1. Mendez D , Warner K E , Courant P N , Has smoking cessation ceased? Expected 
trends in the prevalence of smoking in the United States. Am J Epidemiol. 
1998 Aug 1;148(3):249–258.
PRS14
PatIentS wIth coPd who InItIate RoflumIlaSt In Sweden
Khalid J.M.1, Mushnikov V.2, Vattulainen P.2, Johansson G.3, Korhonen P.2, Hoti F.2
1Takeda Development Centre Europe, Ltd., London, UK, 2EPID Research, Espoo, Finland, 3Uppsala 
University, Uppsala, Sweden
objeCtives: In Sweden, reimbursement for roflumilast is limited to eligible patients 
with severe to very severe chronic obstructive pulmonary disease (COPD) who are 
intolerant to inhaled corticosteroid therapy. Therefore, patients being treated 
with roflumilast in Sweden may differ by their characteristics to patients in other 
countries. Our aim was to describe demographic and disease characteristics of 
patients with COPD prescribed roflumilast in Sweden, at time of first prescrip-
tion. Methods: Patients with diagnoses of COPD or chronic bronchitis (CB) who 
initiated use of roflumilast at age ≥ 40 during 2011 were identified from the Swedish 
Hospital Discharge Register and Swedish Prescribed Drug Register. Summary sta-
tistics were calculated for demographic and disease characteristics at time of first 
prescription. The Charlson comorbidity index (CCI) was used to score the pres-
ence of comorbidities. Results: 1,161 patients (42.8% male) with COPD/CB initi-
ated roflumilast. Mean age at time of first prescription was 70.8 (SD±8.3) years. 
Mean time since first COPD diagnosis was 6.1 (SD±3.8) years. 640 (55.1%) patients 
were hospitalized at least once in the year prior; 99 (8.5%) had ≥ 5 hospitalisations 
in this period. 21.7% of patients had congestive heart failure, 13.5% myocardial 
infarction, 17.1% diabetes, and 9.1% a mood disorder indicated in their medical 
records. 37.2% of patients had a CCI score ≥ 3 at time of first roflumilast prescrip-
tion. ConClusions: Patients who are prescribed roflumilast carry a very severe 
disease burden. Appropriate methodology should be used when making compari-
sons between patients who are exposed to roflumilast to those who are not, using 
real world data in Sweden.
PRS15
the PRevalence of tobacco SmokIng In PatIentS wIth dIabeteS In 
hoSPItal Pulau PInang, malaySIa
Albaroodi K.A.I.1, Syed Sulaiman S.A.2, Shafie A.A.3, Awaisu A.4, Lajis R.1
1University Sains Malaysia, Pulau Penang, Malaysia, 2Universiti Sains Malaysia, Minden, 
Malaysia, 3Universiti Sains Malaysia, Penang, Malaysia, 4Qatar University, Doha, Qatar
Widespread evidence has demonstrated the negative effects of tobacco smoking 
in patients with diabetes. Although many studies have explored the prevalence of 
tobacco smoking in the general population, data are lacking regarding its preva-
lence in a specific population with a chronic disease such as diabetes.objeCtives: 
This study aims to determine the prevalence of tobacco smoking among patients 
with diabetes in Hospital Pulau Pinang, Malaysia. Methods: A cross-sectional 
survey was conducted to study diabetic patients who attended the endocrine 
clinic at Hospital Pulau Pinang in Malaysia from March to August 2012. All the 
diabetic patients who attended the endocrine clinic during that period were 
asked about their smoking status, and their medical records were reviewed. A 
total of 1,118 patients with diabetes were reviewed to determine the prevalence 
of tobacco smoking in diabetic patients at the endocrine clinic of Hospital Pulau 
Pinang. Results: The majority of the study population was male, with Malay 
and Chinese patients in almost equal proportions and a smaller proportion of 
Indian patients. Most of these patients had started smoking before they were diag-
nosed with diabetes. Among the 1,118 diabetic patients, only 108 patients smoked; 
therefore, the prevalence of tobacco smoking in our patients with diabetes was 
9.66%. ConClusions: A low prevalence of tobacco smoking was estimated in 
this study. This prevalence is close to the corresponding value in the general 
population in Malaysia.
PRS16
cuRRent annual coSt calculatIon IS the beSt PRedIctoR of 
moRtalIty at thRee yeaRS In coPd
Dal negro RW
Nationa center for Respiratory Pharmacoeconomics & Pharmacoepidemiology, Verona, Italy
objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a progressive con-
dition which is characterized by a dramatic socio-economic impact. Sensitivity of 
clinical signs and lung function in predicting death is variable in different COPD 
phenotypes. AiM: To assess the predictive value of COPD annual cost on mortal-
ity. Methods: Gender; age; smoking habit, clinical data, and complete lung fun-
tion were assessed in 275 consecutive COPD patients aged > 40y together with the 
annual cost calculated over the last twelve months. stAtistiCs: t test for com-
paring means ± sd; linear regression for checking any relationship between each 
variable and mortality (p< 0.05 was accepted). Results: The whole mortality was 
40.4% over three years (n= 12; 47, and 52 subjects, respectively). Subjects still sur-
vived after three years (n= 164) proved originally different from those (n= 111) who 
died in terms of mean age; FEV1 (in l); RV; TLCO/VA; 6’ walking test; BODE index, and 
Charlson index (all p< 0.001), but not of FEV1% pred. and FEV1/FVC (p= ns). Mean total 
(29.0%), venom 31 (8.0%), drug 28 (7.2%), other/unknown 217 (55.8%). The prescrip-
tion rate of self-injection epinephrine immediately after the anaphylaxis was 10.9% 
(after the insurance started to cover the service in 2011/9). ConClusions: This 
is the first report on the incidence of anaphylaxis in general population in Japan; 
the rates were consistent with those reported in the West. The prescription rate of 
self-injection epinephrine was notably low even among those who experienced 
anaphylaxis, indicating the importance of increasing the awareness of the avail-
ability of life-saving anaphylaxis management.
PRS11
ePIdemIology and SeveRIty of chRonIc obStRuctIve PulmonaRy 
dISeaSe (coPd) In the unIted kIngdom (uk)
Raluy-Callado M1, Lambrelli D1, MacLachlan S1, Merinopoulou E1, Hagan MA2, Khalid JM3
1Evidera, London, UK, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 3Takeda 
Development Centre Europe, Ltd., London, UK
objeCtives: In 2013, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) recommendations on COPD management and prevention were updated 
to include additional therapeutic options for patients based on severity using a 
combined assessment of symptoms, degree of airflow limitation and number of 
exacerbations. The objective of the present study was to quantify the prevalence and 
incidence of COPD in the UK and estimate disease severity by 2013 GOLD categories 
A/B (low risk) and C/D (high risk). Methods: Patients with a diagnosis of COPD 
aged ≥ 40 years were identified in the population-based Clinical Practice Research 
Datalink. Point prevalence was calculated on December 31, 2013. Incidence was 
estimated using newly diagnosed patients between 2009-2013. Rates were standard-
ised using 2011 UK population age and gender. % predicted FEV1, modified British 
Medical Research Council grade and exacerbations defined by Read codes and pre-
scriptions were used to classify patients by GOLD categories. Patient characteristics 
were reported. Results: 49,286 prevalent patients were diagnosed with COPD with 
mean age of 70 years; 51% were male. Median time since diagnosis was 5 years. 
Overall prevalence was 33.0 per 1,000 people (95% CI: 32.7-33.4). Of these, 66.4% were 
classified as GOLD A/B and 33.6% as GOLD C/D. 27,224 newly diagnosed patients were 
identified with mean age of 67 years at first diagnosis; 53% were male. Incidence 
was 2.2 per 1000 person-years (95% CI: 2.1-2.2). ConClusions: A third of COPD 
patients in the UK are considered high-risk according to the 2013 GOLD categories. 
Classification of patients is key to identifying appropriate treatment options to 
reduce symptoms and the frequency of COPD exacerbations.
PRS12
IncIdence and PRevalence of coPd by gold 2013 claSSIfIcatIon In the 
netheRlandS
Van den Berg E.J.1, Overbeek J.A.1, Penning-van Beest F.J.A.1, Khalid J.M.2, Dekhuijzen P.N.R.3, 
Herings R.1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Takeda Development 
Centre Europe, Ltd., London, UK, 3Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands
objeCtives: To quantify the five-year incidence (2008-2012) and 2012 prevalence 
of COPD in The Netherlands by the Global initiative for chronic Obstructive Lung 
Disease (GOLD) 2013 combined assessment categories. Methods: Using the 
General Practitioners Database of the PHARMO Database Network, the five-year 
incidence (2008-2012) and prevalence at July 1, 2012 of COPD (ICPC code R95) by 
GOLD 2013 combined assessment categories among individuals ≥ 40 years of age 
was assessed. Based on degree of airflow limitation (using post-bronchodilator 
FEV1) and risk of exacerbations (based on medication or as recorded by the GP) 
patients were classified as low-risk COPD (FEV1 ≥ 50% and/or ≤ 1 exacerbations) or 
high-risk COPD (FEV1 < 50% and/or ≥ 2 exacerbations). Results: Using a source 
population of 813,800 individuals ≥ 40 years of age the five-year (2008-2012) inci-
dence (95% CI) of COPD among patients ≥ 40 years of age was 0.50 (0.49-0.50) per 
100 person years; this was 0.54 (0.53-0.55) among males and 0.45 (0.44-0.46) among 
females. The 2012 prevalence of COPD in a source population of 805,112 individu-
als ≥ 40 years of age was 3.7 (3.6-3.7) per 100 persons; this was 4.0 (3.9-4.1) among 
males and 3.4 (3.3-3.4) among females. Mean (± sd) age of incident and prevalent 
COPD patients was 65 ± 12 and 67 ± 12 years, respectively. The distribution of low-
risk COPD and high-risk COPD was 90% versus 10%. For patients treated by their 
GP this distribution of low-risk and high-risk COPD was similar, while patients 
treated by a specialist had a distribution of 82% versus 18%. ConClusions: This 
study describes the epidemiology of COPD in the Netherlands. Results on the 
distribution of low-risk and high-risk COPD depend on the population studied and 
the definitions used. Additional information on symptoms would allow a more 
detailed classification of patients.
PRS13
eStImatIng SmokIng ceSSatIon RateS and SmokIng PRevalenceS uSIng 
PublIc data and a PublIShed dynamIc model
Kumar R., Govindan B.
Vantage Research, Chennai, India
objeCtives: Mendez et al1 developed a dynamic forecasting model to predict 
the prevalence of smoking. They use initiation and prevalence rates (data from 
1965-1993) and estimate cessation rates for that period. Further, they assume the 
persistence of the cessation rates and predict future prevalence of smoking. We 
re-created the Mendez et al model in order to estimate smoking cessation rates (n) 
and updated cessation rates for 2000-2012 using newly available data on smoking 
prevalence (R). Further, smoking prevalences for the decade 2012-2024 were pre-
dicted based on a couple of alternate hypotheses of smoking initiation Methods: 
We re-created the Mendez model in Excel, including the mathematical manipu-
lations for estimates of mean rates of cessation from the years 1970-1994 and 
used the re-created Mendez model set-up and newly available data on smok-
ing prevalence (R), initiation etc. to estimate cessation rates between 2001 and 
2012. Further, we predicted smoking prevalences for 2012-2024 and explored a 
